You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,062,643


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,062,643
Title:Use of neurotoxin therapy for treatment of urologic and related disorders
Abstract: The present invention related to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.
Inventor(s): Schmidt; Richard A (Arvada, CO)
Assignee: The Regents of the University of Colorado (Boulder, CO)
Application Number:11/925,938
Patent Claims:1. A method for treating an urge type dysfunction in a patient, comprising administering a therapeutically effective amount of between 1.4 IU/kg to 17.1 IU/kg of botulinum toxin to a lateral bladder wall of the bladder of the patient, whereby the urge type dysfunction is treated.

2. The method of claim 1, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.

3. The method of claim 2, wherein the botulinum toxin is botulinum toxin type A.

4. The method of claim 3, wherein administration is to a bladder wall and administration is by single or serial injection.

5. The method of claim 3, wherein the therapeutically effective amount of botulinum toxin type A is 200 IU of botulinum toxin type A.

6. The method of claim 3, wherein the therapeutically effective amount of botulinum toxin type A is 400 IU of botulinum toxin type A.

7. The method of claim 3, wherein the therapeutically effective amount of botulinum toxin type A is 400 IU of botulinum toxin type A administered serially.

8. The method of claim 1, wherein administration is by injection.

9. The method of claim 8, wherein injection comprises a single injection.

10. The method of claim 8, wherein injection comprises serial injection.

11. The method of claim 1, wherein treating the urge type dysfunction provides the patient with sleep through the night that is uninterrupted by an urge to urinate.

12. The method of claim 1, wherein the botulinum toxin is administered in a pharmaceutically acceptable formulation.

13. A method for treating an urge type dysfunction in a patient, the method comprising administering, via injection, a therapeutically effective amount of between about 1.4 IU/kg and about 17.1 IU/kg of a botulinum toxin type A to a bladder of the patient, whereby the urge type dysfunction is treated.

14. The method of claim 13, wherein the therapeutically effective amount of botulinum toxin type A is 200 IU of botulinum toxin type A.

15. The method of claim 13, wherein the therapeutically effective amount of botulinum toxin type A is 400 IU of botulinum toxin type A.

16. The method of claim 13, wherein the therapeutically effective amount of botulinum toxin type A is 400 IU of botulinum toxin type A administered serially.

17. The method of claim 13, wherein the therapeutically effective amount is provided as a single dose.

18. The method of claim 13, wherein the therapeutically effective amount is provided as a divided dose.

19. The method of claim 13, wherein frequency of urination during sleep is reduced.

20. The method of claim 13, wherein the therapeutically effective amount is administered to a lateral wall of the bladder.

21. The method of claim 13, wherein the botulinum toxin is administered in a pharmaceutically acceptable formulation.

International Patent Family for US Patent 8,062,643

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 9903483 ⤷  Try a Trial
United States of America 9066943 ⤷  Try a Trial
United States of America 8840905 ⤷  Try a Trial
United States of America 8057807 ⤷  Try a Trial
United States of America 7968104 ⤷  Try a Trial
United States of America 7470431 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.